Saracatinib

• CAT Number: I003391
• CAS Number: 379231-04-6
• Molecular Formula: C₂₇H₃₂ClN₅O₅
• Molecular Weight: 542.03
• Purity: 98%
• Synonyms: N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(oxan-4-yloxy)quinazolin-4-amine; Saracatinib (AZD0530)
• Target: Bcr-Abl
• Solubility: DMSO: ≥ 44 mg/mL
• Storage: 3 years -20C powder
• IC50: 2.7 nM(c-Src); 30 nM (v-Abl)
• IUPAC Name: N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(oxan-4-yloxy)quinazolin-4-amine
• InChI: InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)
• InChIKey: OUKYUETWWIPKQR-UHFFFAOYSA-N
• SMILES: CN1CCN(CC1)CCOC2=CC3=C(C(=C2)OC4CCOCC4)C(=NC=N3)NC5=C(C=CC6=C5OCO6)Cl

Saracatinib（Cat No.:I003391）is a potent and selective Src kinase inhibitor essential for advanced cancer research. By targeting the Src family of tyrosine kinases, it plays a critical role in studying signal transduction pathways involved in cancer progression and metastasis. This high-purity compound ensures precise and reliable analytical results, making it ideal for experimental setups focused on oncological research and drug development. Its stability and efficacy support robust investigations into novel cancer therapies, offering significant potential in the fight against various malignancies and enhancing the understanding of cancer biology.